✨ Free AI Report
Curis, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Curis, Inc.
Company Research

Curis, Inc.: Business Overview, Financials & Competitive Analysis

Curis is a publicly-traded biotechnology company (NASDAQ: CRIS) focused on the development of first-in-class and innovative therapeutics for the treatment of cancer. The company recently transitioned to a pure-play, p...

Analyst-debate audio for Curis, Inc.

AskCyborg analysts argue the bull and bear cases for Curis, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
4/ 10Mixed

Cyborg Score thesis

High-risk, high-reward pure-play oncology biotech betting entirely on emavusertib success with acute near-term financing...

Read the full analyst-debate transcript →
Industry Clinical-stage oncology biotechnology; focus on targeted immuno-oncology and precision medicine for hematologic malignancies and solid tumors
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 2, 2026
AI-Generated Research
30+ Page Report

Get the Latest Curis, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Curis, Inc. Overview

Pro stress-test →

Curis is a publicly-traded biotechnology company (NASDAQ: CRIS) focused on the development of first-in-class and innovative therapeutics for the treatment of cancer. The company recently transitioned to a pure-play, pre-commercial biotech after selling its remaining interest in the Erivedge royalty stream in November 2025.

Strategic Profile

Pro stress-test →

Curis is a clinical-stage biotechnology company advancing targeted therapies for cancer treatment, with a focus on immuno-oncology and precision medicine. The company's lead asset, emavusertib, an IRAK4 inhibitor, recently showed a promising 50% MRD conversion rate in a July 2025 data cut-off for its AML triplet study, a critical clinical milestone that could dramatically change its valuation.

Competitive Landscape

Pro stress-test →

Curis's pipeline includes Emavusertib (oral IRAK4 inhibitor in Phase 1/2 for R/R AML/MDS), Fimepinostat (HDAC/PI3K dual inhibitor for B-cell lymphoma), CA-170 (PD-L1/VISTA antagonist), and CA-327 (TIM3/PD-L1 antagonist). Competitors in immuno-oncology include Incyte (Opzelura/ruxolitinib), Celldex (glembatumumab vedotin), and various checkpoint inhibitor programs from large pharma (Merck, Bristol Myers Squibb, Roche/Genentech partnerships).

Industry Context

Curis, Inc. operates in Clinical-stage oncology biotechnology; focus on targeted immuno-oncology and precision medicine for hematologic malignancies and solid tumors.

Key facts

Founded: 2000 · Headquarters: Lexington, Massachusetts · Revenue: $11.65M (TTM, Erivedge royalties) · Market cap: $13.4M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Curis, Inc..

  • Pure-play transition: Eliminated legacy Erivedge royalty income ($3.2M quarterly) in November 2025 to strengthen balance sheet, now entirely pipeline-dependent
  • Lead candidate momentum: Emavusertib achieved 50% MRD conversion in AML triplet combination trial (July 2025 data), supporting potential accelerated approval pathway in R/R PCNSL
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • November 2025Sold remaining Erivedge royalty interest for $2.5M, extinguishing $28.6M liability; transitioned to pure-play biotech
  • July 2025Emavusertib showed 50% MRD conversion rate in AML triplet combination study with venetoclax/azacitidine
  • +1 moreTrack every material event for Curis, Inc. as it happens. Explore monitoring →
Get alerted when Curis, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Opzelura/RuxolitinibJAK inhibitor for cutaneous T-cell lymphoma; competitive immuno-oncology play→Checkpoint inhibitors (PD-1/PD-L1/CTLA-4)Established immuno-oncology standard of care; large pharma competition→HDAC inhibitorsCompeting HDAC/epigenetic modulation approaches for lymphomas→

Compare Curis, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Curis, Inc. operates in Clinical-stage oncology biotechnology; focus on targeted immuno-oncology and precision medicine for hematologic malignancies and solid tumors. See how the rest of the sector scores on the Cyborg framework.

Browse Clinical-stage oncology biotechnology; focus on targeted immuno-oncology and precision medicine for hematologic malignancies and solid tumors research →
NEW · MCP server

Ask your AI assistant about Curis, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Curis, Inc. and its top competitor on Cyborg Score”
“What did Curis, Inc. do this quarter?”
“Is Curis, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Curis, Inc. do?+
Curis is a publicly-traded biotechnology company (NASDAQ: CRIS) focused on the development of first-in-class and innovative therapeutics for the treatment of cancer. The company recently transitioned to a pure-play, p...
What is Curis, Inc.'s Cyborg Score?+
Curis, Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Curis, Inc.'s main competitors?+
Named competitors include Opzelura/Ruxolitinib, Checkpoint inhibitors (PD-1/PD-L1/CTLA-4), HDAC inhibitors. The full competitive landscape is in the AskCyborg report.
How can I get the full Curis, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Curis, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Curis, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.